The following is a summary of “Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis,” published in the January 2025 issue of Psychiatry by Fountoulakis et al.

Medicaid in Wisconsin has expanded to cover ketamine infusions as of Jan. 1, sparking conversations about the nuances in type ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...

Ketamine-assisted therapy lifted me out of depression. But it remains costly — and controversial Health Canada approved a ...

( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Legal Disclaimer: ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Esketamine, a derivative of ketamine, is a rapid-acting antidepressant. Previously, it was approved in combination with oral antidepressants for individuals with treatment-resistant depression.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...